Immunopathogenesis of multiple sclerosis: The role of T cells

Current Opinion in Neurology

Volumn 12, Issue 3, 1999, Pages 309-321

  Martino, Gianvito ^a   Hartung, Hans Peter ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLYCOPROTEIN; MYELIN; MYELIN BASIC PROTEIN; PROTEOLIPID PROTEIN;

AUTOIMMUNITY; CELLULAR IMMUNITY; DEMYELINATION; HUMAN; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

HUMANS; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 0032772860     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199906000-00010     Document Type: Review

References (145)

1. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of non specific cells: a tale of smart bombs and the infantry. Proc Natl Acad Sci U S A 1996; 93:2253-2256.
2. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995; 32:121-182.
3. Zhang YD, Burger D, Saruhan M, Jeannet M, Steck AJ. The T-lymphocyte response against myelin-associated glycoprotein and myelin basic protein in patients. Neurology 1993; 43:403-407.
4. Link H, Sun JB, Wang Z, Xu Z, Love A, Frederikson S, Olsson T. Virus-specific and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992; 38:63-74.
5. Burns J, Rosenzweig A, Zweiman B, Lisak RP. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 1983; 81:435-440.
6. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346:183-187.
7. + cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol 1992; 148:1359-1366.
8. Pette M, Fujita K, Kitze B, Whitaker JN, Albert E, Kappos L, Wekerle H. Myelin basic protein-specific T lymphocyte lines from multiple sclerosis patients and healthy individuals. Neurology 1990; 40:1770-1776.
9. Olsson T, Wei Zhi W, Hojeberg B, Kostulas V, Yu-Ping J, Anderson G, et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ. J Clin Invest 1990; 86:981-985.
10. Olsson T, Sun J, Hillert J, Hojeberg B, Ekre HP, Andersson G, et al. Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis. Eur J Immunol 1992; 22:1083-1087.
11. Bieganowska KD, Ausbel LJ, Modaber Y, Slovik E, Messersmith W, Hafler DA. Direct ex vivo analysis of activated Fas-sensitive autoreactive T cells in human autoimmune disease. J Exp Med 1997; 185:1585-1594.
12. Joshi N, Usuku K, Hauser SL. The T-cell response to myelin basic protein in familial multiple sclerosis: diversity of fine specificity, restricting elements, and T-cell receptor usage. Ann Neurol 1993; 34:385-393.
13. Martin R, Voskuhl R, Flerlage M, McFarlin DE, McFarland HF. Myelin basic protein-specific T-cell responses in identical twins discordant or concordant for multiple sclerosis. Ann Neurol 1993; 34:524-535.
14. + T-cell responses to human myelin protein-derived peptides. Proc Natl Acad Sci USA 1994; 91:10859-10863.
15. + cytotoxic T cells can contribute to the tissue injury in multiple sclerosis.
16. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T Cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990; 247:718-721.
17. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179:973-984.
18. Bieganowska KD, Ausubel LJ, Modabber Y, Slovik E, Messersmith W, Hafler DA. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J Exp Med 1997; 185:1585-1594.
19. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. J Clin Invest 1998; 101:725-730. The results obtained suggest that MBP-reactive T cells are more likely to have been activated in vivo or differentiated into memory T cells in multiple sclerosis patients compared with in control individuals.
20. + T cells in patients with multiple sclerosis are costimulation independent and have been previously activated in vivo.
21. Burns J, Bartholomew B, Lobo S. Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis. Ann Neurol 1999; 45:33-39. These results suggest that a substantial proportion of MBP-reactive T cells from some patients with multiple sclerosis have been previously activated in vivo.
22. Richert JR, Reuben-Burnside CA, Deibler GE, Kies MW. Peptide specificities of myelin basic protein-reactive human T-cell clones. Neurology 1998; 38:739-742.
23. Pette M, Fujita K, Wilkinson D, Altmann DM, Trowsdale J, Giegerich G, et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors. Proc Natl Acad Sci U S A 1990; 87:7968-7972.
24. Martin R, Howell MD, Jaraquemada D, Flerlage M, Richert J, Brostoff S, et al. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med 1991; 173:19-24.
25. Meinl E, Weber F, Drexler K, Morelle C, Ott M, Saruhan-Direskeneli G, et al. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 1993; 92:2633-2643.
26. Vergelli M, Kalbus M, Rojo SC, Hemmer B, Kalbacher H, Tranquill L, et al. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells. J Neuroimmunol 1997; 77:195-203.
27. Muraro PA, Vergelli M, Kalbus M, Banks DE, Nagle JW, Tranquill LR, et al. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell repertoire. J Clin Invest 1997; 100:339-349.
28. Steinman L, Waisman A, Altman D. Major T-cell responses in multiple sclerosis. Mol Med Today 1995; 1:79-83.
29. Valli A, Sette A, Kappos L, Oseroff C, Sidney J, Miescher G, et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993; 91:616-628.
30. Vogt AB, Kropshofer H, Kalbacher H, Kalbus M, Rammensee H-G, Coligan JE, Martin R. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J Immunol 1994; 153:1665-1673.
31. Wucherpfennig KW, Sette A, Southwood S, Oseroff C, Matsui M, Strominger JL, Hafler DA. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 1994; 179:279-290.
32. Oksenber JR, Panzara MA, Begovich AB, Mitchell D, Erlich HA, Murray RS, et al. Selection for T-cell receptor Vb-Db-Jb gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 1993; 362:68-70.
33. Allegretta M, Albertini RJ, Howell MD, Smith LR, Martin R, McFarland HF, et al. Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis. J Clin Invest 1994; 94:105-109.
34. Kozovska M, Zang YC, Aebischer I, Lnu S, Rivera VM, Crowe PD, et al. T cell recognition motifs of an immunodominant peptide of myelin basic protein in patients with multiple sclerosis: structural requirements and clinical implications. Eur J Immunol 1998; 28:1894-1901. This study shows that two central residues (Phe90 and Lys91) served as the critical TCR contact points for both DR2-restricted and DR4-restricted T-cell clones. A single alanine substitution at residue 90 or residue 91 abolished the responses of 81-95% of the TCCs, whereas a double alanine substitution rendered all TCCs unresponsive.
35. Hemmer B, Vergelli M, Tranquill L, Conlon P, Ling N, McFarland HF, Martin R. Human T-cell response to myelin basic protein peptide (83-99): extensive heterogeneity in antigen recognition, function and phenotype. Neurology 1997; 49:1116-1126.
36. Wucherpfennig KW, Ota K, Endo N, Seidman JG, Rosenzwei, A, Weiner HL, Hafler DA. Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science 1990; 248:1016-1019.
37. Kotzin BL, Karuturi S, Chou YK, Lafferty J, Forrester M, Better M, et al. Preferential T-cell receptor Vb-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Proc Natl Acad Sci U S A 1991; 88:9161-9165.
38. Vergelli M, Hemmer B, Utz U, Vogt A, Kalbus M, Tranquill L, et al. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99). Eur J Immunol 1996; 26:2624-2634.
39. Wucherpfennig KW, Zhang J, Witek C, Matsui M, Modabber Y, Ota K, Hafler DA. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994; 152:5581-5592.
40. Hafler DA, Saadeh MG, Kuchroo V, Milford E, Steinman L. TCR usage in human and experimental demyelinating diseases. Immunol Today 1996; 17:152-159.
41. Zhang YC, Kozovska M, Aebischer I, Li S, Boehme S, Crowe P, et al. Restricted TCR Valpha gene rearrangements in T cells recognizing an immunodominant peptide of myelin basic protein in DR2 patients with multiple sclerosis. Intern Immunol 1998; 10:991-998.
42. Ben-Nun A, Liblau RS, Cohen L, Lehmann D, Tournier-Lasserve E, Rosenzweig A, et al. Restricted T-cell receptor V beta gene usage by myelin basic protein-specific T-cell clones in multiple sclerosis: predominant genes vary in individuals. Proc Natl Acad Sci U S A 1991; 88:2466-2470.
43. Salvetti M, Ristori G, D'Amato M, Buttinelli C, Falcone M, Fieschi C, et al. Predominant and stable T cell responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis. Eur J Immuol 1993; 23:1232-1239.
44. Uccelli A, Giunti D, Salvetti M, Ristori G, Fenoglio D, Abruzzese A, Mancardi G. A restricted response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. Clin Exp Immunol 1998; 111:186-192.
45. Jaraquemada D, Martin R, Rosen-Bronson S, Flerlage M, McFarland HF, Long EO. HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals. J Immunol 1990; 145:2880-2685.
46. Martin R, Jaraquemada D, Flerlage M, Richert J, Whitaker J, Long EO, et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol. 1990; 145:540-548.
47. + myelin reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. J Immunol 1996; 157:679-688.
48. + TCCs specific for myelin basic protein, regardless of their cytokine phenotype, can be reither noncytotoxic or lyse target cells via either perforin- or Fas/Fas ligand-mediated cytotoxicity.
49. Hemmer B, Vergelli M, Pinilla C, Houghten RA, Martin R. Probing degeneracy in T-cell recognition using peptide combinatorial libraries-importance for T-cell survival and autoimmunity. Immunol Today 1998; 19:163-168.
50. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998; 19:395-404.
51. Vergelli M, Hemmer B, Kalbus M, Vogt AB, Ling N, Conlon P, et al. Modifications of peptide ligands enhancing T cell responsiveness suggest a broad spectrum of stimulatory ligands for autoreactive T cells. J Immunol 1997; 158:3746-3752.
52. Hemmer B, Fleckenstein BT, Vergelli M, Jung W, McFarland H, Martin R, Wiesmuller KH. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J Exp Med 1997; 185:1651-1659.
53. + memory) from patients with multiple sclerosis can be activated by proinflammatory cytokines, bypassing the TCR engagment via two independent calcium-mediated intracellular pathways.
54. Unutmaz D, Pileri P, Abrignani S. Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J Exp Med 1994; 180:1159-1164.
55. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272:1947-1950.
56. Ehl S, Hombach J, Aichele P, Hengartner H, Zinkernagel RM. Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med 1997; 185:1241-1251.
57. Talbot PJ, Paquette JS, Ciurli C, Antel JP, Ouellet F. Myelin basic protein and human coronavirus 229E cross-reactive T cells in multiple sclerosis. Ann Neurol 1996; 39:233-240.
58. Birnbaum G, Kotilinek L, Schlievert P, Clark HB, Trotter J, Horvath E, et al. Heat shock proteins and experimental autoimmune encephalomyelitis (EAE): I. Immunization with a peptide of the myelin protein 2′, 3′ cyclic nucleotide ' phosphodiesterase that is cross-reactive with a heat shock protein alters the course of EAE. J Neurosci Res 1996; 44:381-396.
59. Wucherpfenning KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80:695-705.
60. Kaufman MD. Do micorbes with peptides mimicking myelin cause multiple sclerosis if the T cell response to their unique peptides is limited? J Theor Biol 1998; 193:691-708. An hypothesis for the pathogenic mechanism of multiple sclerosis based upon assumptions about the response of the T-cell repertoire to pathogens is presented.
61. Trotter JL, Hickey WF, van der Veen RC, Sulze L. Peripheral blood mononuclear cells from multiple sclerosis patients recognize myelin proteolipid protein and selected peptides. J Neuroimmunol 1991; 33:55-62.
62. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, Frederickson S, et al. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991; 21:1461-1468.
63. + T cells from multiple sclerosis. J Neuroimmunol 1993; 46:33-42.
64. + T cells from multiple patients. J Neuroimmunol 1994; 53:153-161.
65. Ohashi T, Yamamura T, Inobe J, Kondo T, Kunishita T, Tabira T. Analysis of proteolipid protein (PLP)-specific T cells in multiple sclerosis:identification of PLP 95-116 as an HLA-DR2, w15-associated determinant. Int Immunol 1995; 7:1771-1778.
66. Markovic-Plese S, Fukaura H, Zhang J, Al-Sabbagh A, Southwood S, Sette A, et al. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J Immunol 1995; 155:982-992.
67. Greer JM, Csurhes PA, Cameron KD, McCombe PA, Good MF, Pender MP. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 1997; 120:1447-1460.
68. Trotter JL, Pelfrey CM, Trotter AM, Selvidge JA, Gushleff KC, Mohanakumar T, McFarland HF. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J Neuroimmunol 1998; 84:172-178. TCLs from HLA-DR15 multiple sclerosis patients recognized peptide 95-117 significantly more often than TCLs from control individuals.
69. Trotter JL, Damico CA, Cross AH, Pelfrey CM, Karr RW, Fu XT, McFarland HF. HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides. J Neuroimmunol 1997; 75:95-103.
70. Greer JM, Csurhes PA, Cameron KD, McCombe PA, Good MF, Pender MP. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 1997; 120:1447-1460.
71. + T cells that are specific for a MBP peptide and a PLP peptide, and that the majority of this chemotactic activity is mediated by interferon-inducible protein 10.
72. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 1997; 99:1682-1690.
73. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 1999; 72: 1-9.
74. Bernard CCA, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 1997; 75:77-88.
75. Genain CP, Nguyen MH, Letvin NL, Pearl R, Davis RL, Adelman M, Hauser SL. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 1995; 96:2966-2974.
76. Genain CP, Abel K, Belmar N, Villinger F, Rosemberg DP, Linington C, et al. Late complication of immune deviation therapy in a non human primate. Science 1996; 274:2054-2057.
77. Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CCA, Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis, Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993; 92:2602-2608.
78. Sun J, Link H, Olsson T, Xiao BG, Andersson G, Ekre HP, et al. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 1991; 146:1490-1495.
79. Kerlero de Rosbo N, Hoffman M, Mendel I, Yust I, Kaje J, Bakimer R, et al. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol 1997; 27:3059-3069.
80. + multiple sclerosis patients in whom a peptide concentration-dependent proliferative response, which was inhibited by the addition of anti-HLA class II antibodies, was observed.
81. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffmann RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-2357.
82. Del Prete G, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991; 88:346-350.
83. Erard F, Wild M-T, Garcia-Sanz JA, Le Gros G. Switch of CD8 T cells to noncytolytic CD8-CD4-cells that make TH2 cytokines and help B cells. Science 1993; 260:1802-1805.
84. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991; 12:256-257.
85. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993; 177:57-68.
86. + islet-specific T cell clone. Science 1990; 249:1433-1436.
87. Nakajima H, Takamori H, Hiyama Y, Tsukada W. The effect of treatment with interferon-gamma on type II collagen-induced arthritis. Clin Exp Immunol 1990; 81:441-445.
88. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-793.
89. Voskuhl RR, Martin R, Bergman C, Dalal M, Ruddle NH, McFarland HF. T helper 1 (TH1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 1993; 15:137-143.
90. Hemmer B, Vergelli M, Calabresi P, Huang T, McFarland HF, Martin R. Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99). J Neurosci Res 1996; 45:852-862.
91. Hermans G, Stinissen P, Hauben L, Van den Berg-Loonen E, Raus J, Zhang J. Cytokine profile of myelin basic protein-reavtive T cells in multiple sclerosis and healthy individuals. Ann Neurol 1997; 42:18-27.
92. Correale J, Gilmore W, McMillan M, Li S, McCarthy K, Le T, Weiner LP. Patterns of Cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 1995; 154:2959-2968.
93. + T cells via CD40 ligand. Proc Natl Aca Sci U S A 1997; 94:599-603.
94. Correale J, McMillan M, Li S, McCarthy K, Le T, Weiner LP. Antigen presentation by autoreactive proteolipid protein peptide-specific T cell clones from chronic progressive multiple sclerosis patients: roles of co-stimulatory B7 molecules and IL-12. J Neuroimmunol 1997; 72:27-43.
95. Panitch NL, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1:893-895.
96. Panitch NL, Hirsch RL, Schindler J, Johnson KP. Treatment of MS with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987; 37:1097-1102.
97. Selmaj KW, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87:949-954.
98. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78:318-323.
99. Young RA. Stress proteins and immunology. Annu Rev Immunol 1990; 8:401-420.
100. DiSouza SD, Antel JP, Freedman MS. Cytokine induction of heat shock protein expression in human oligodendrocytes: an interleukin-1 mediated mechanism. J Neuroimmunol 1994; 50:17-24.
101. Satoh J, Kim SU. Constitutive and inducible expression of heat shock protein HSP72 in oligodendrocytes in culture. NeuroReport 1995; 6:1081-1084.
102. Aquino DA, Lopez C, Farooq M. Antisense oilgonucleotide to the 70-kDa heat shock protein inhibits synthesis of myelin basic protein. Neurochem Res 1996; 21:417-422.
103. Brosnan CF, Battistini L, Gao YL, Raine CS, Aquino DA. Heat shock proteins and multiple sclerosis. J Neuropathol Exp Neurol 1996; 55:389-402.
104. Aquino DA, Capello E, Weisstein J, Sanders V, Lopez C, Tourtellotte WW, et al. Multiple sclerosis: altered expression of 70- and 27-kDa heat shock proteins in lesions and myelin. J Neuropathol Exp Neurol 1997; 56:664-672.
105. Bajramovic JJ, Lassmann H, van Noort JM. Expression of aB-crystallin in glia cells during lesional development in multiple sclerosis. J Neuroimmunol 1997; 78:143-151.
106. Stinissen P, Vandevyver C, Medaer R, Vandegaer L, Nies J, Tuyls L, et al. Increased frequency of γδ T cells in the cerebrospinal fluid and peripheral blood of patients with multiple sclerosis: reactivity, cytotoxicity and T cell receptor V gene rearrangements. J Immunol 1995; 154:4883-4894.
107. van Noort JM, van Sechel AC, Bajramovic JJ, el Ouagmiri M, Polman CH, Lassmann H, Ravid R. The small heat shock protein alpha-B crystallin as a candidate autoantigen in multiple sclerosis. Nature 1995; 376:798-801.
108. van Sechel AC, van Stipdonk MJB, Persoon-Deen C, van Noort JM. Epstein-Barr virus induced expression and HLA-DR restricted presentation of aB-crystallin, a major human myelin antigen [Abstract]. J Neuroimmunol 1998; 90:38.
109. Salvetti M, Buttinelli C, Ristori G, Carbonari M, Cherchi M, Fiorelli M, et al. T-lymphocyte reactivity to the recombinant mycobacterial 65- and 70-kD heat shock proteins in multiple sclerosis. J Autoimmunity 1992; 5:691-702.
110. Salvetti M, Ristori G, Buttinelli C, Fiori P, Falcone M, Britton W, et al. The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis. J Neuroimmunol 1996; 65:143-153.
111. Banki K, Colombo E, Sia F, Halladay D, Mattson DH, Tatum AH, et al. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J Exp Med 1994; 180:1649-1663.
112. Colombo E, Banki K, Tatum AH, Daucher J, Ferrante P, Murray RS, et al. Comparative analysis of antibody and cell-mediated autoimmunity to transaldolase and myelin basic protein in patients with multiple sclerosis. J Clin Invest 1997; 99:1238-1250.
113. Walsh MJ, Murray JM. Dual implication of 2′,3′-cyclic nucleotide 3′ phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis. J Clin Invest 1998; 101:1923-1931.
114. Rosener M, Muraro PA, Riethmuller A, Kalbus M, Sappler G, Thompson RJ, et al. 2′-3′-cyclic nucleotide 3′-phosphodiesterase: a novel candidate autoantigen in demyelinating diseases. J Neuroimmunol 1997; 75:28-34.
115. + T cells specific for an astrocyte protein, S100 beta. J Neural Transm 1997; 49 (Suppl):43-51.
116. Schmidt S, Linnington C, Zipp F, Sotgiu S, de Waal Malefyt R, Wekerle H, Hohlfeld R. Multiple sclerosis: comparison of the human T cell response to S100 beta and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. Brain 1997; 120:1437-1445.
117. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996; 272:50-53.
118. + cells: new clues to their origin, specificity, and function. J Exp Med 1995; 182:633-638.
119. Battistini L, Selmaj K, Kowal C, Ohmen J, Modlin RL, Raince CS, Brosnan CF. Multiple sclerosis: limited diversity of the V delta 2-J delta 3 T-cell receptor in chronic active lesions. Ann Neurol 1995; 37:198-203.
120. Selmaj K, Brosnan CF, Raine CS. Colocalization of lymphocytes bearing gamma delta T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis. Proc Natl Acad Sci U S A 1991; 88:6452-6456.
121. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA. Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci U S A 1992; 89:4588-4592.
122. Liedtke W, Meyer G, Faustmann PM, Warnatz H, Raine CS. Clonal expansion and decreased occurrence of peripheral blood gamma delta T cells of V delta 2J delata 3 lineage in multiple sclerosis patients. Int Immunol 1997; 9:1031-1041.
123. Freedman MS, Ruijs TCG, Selin LK, Antel JP. Peripheral blood gamma-delta T cells lyse fresh human brain-derived oligodendrocytes. Ann Neurol 1991; 30:794-800.
124. Zeine R, Pon R, Ladiwala U, Antel JP, Filion LG, Freedman MS. Mechanism of gamma delta T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis. J Neuroimmunol 1998; 87:49-61. The results of this study suggest that in multiple sclerosis γ/δ T cells may utilize either the Fas-mediated or perforin-based cell cytotoxicity pathways in exerting oligodendrocyte damage. Among them, the perforin pathway is predominant.
125. Boismenu R, Feng L, Xia YY, Chang JC, Havran WL. Chemokine expression by intraepithelial gamma delta T cells. Implications for the recruitment of inflammatory cells to damaged epithelia. J Immunol 1996; 157:985-992.
126. Rajan AJ, Gao Y-L, Raine CS, Brosnan CF. A pathogenic role for gamma delta T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse. J Immunol 1996; 157:941-949.
127. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997; 15:535-562.
128. Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med 1993; 178:1-16.
129. Dellabona P, Radovan E, Casorati G, Brockhaus M, Lanzavecchia A. An invariant V alpha 24-J alpha O/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J Exp Med 1994; 180:1171-1176.
130. + T cells in a TH2 response and in immunoglobulin E production. Science 1995; 270:1845-1847.
131. Yoshimoto T, Paul WE. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994; 179:1285-1295.
132. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, Kronenberg M. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998; 188:1521-1528.
133. + T cells that promptly produce interleukin 4. Proc Natl Acad Sci U S A 1995; 92:11931-11934.
134. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998; 391:177-181.
135. + T cell development in CD3 zeta-deficient mice. J Exp Med 1995; 182:891-895.
136. Battistini L, Borsellino G, Sawicki G, Poccia F, Salvetti M, Ristori G, Brosnan CF. Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. J Immunol 1997; 159:3723-3730.
137. Battistini L, Fisher F, Raine CS, Brosnan CF. CD1b is expressed in multiple sclerosis lesions. J Neuroimmunol 1996; 67:145-151.
138. Mandelboim O, Davis DM, Reyburn HT, Vales-Gomez M, Sheu EG, Pazmany L, Strominger JL. Enhancement of class II-restricted T cell responses by costimulatory NK receptors for class I MHC proteins. Science 1996; 274:2097-2100.
139. Offner H, Vainiene M, Gold DP, Morrison WJ, Wang RY, Hashim GA, Vandenbark AA. Protection against experimental encephalomyelitis. Idiotypic autoregulation induced by a nonencephalitogenic T cell clone expressing a cross-reactive T cell receptor V gene. J Immunol 1991; 146:4165-4172.
140. Hashim GA, Offner H, Wang RY, Shukla K, Carvalho E, Morrison WJ, Vandenbark AA. Spontaneous development of protective anti-T cell receptor autoimmunity targeted against a natural EAE-regulatory idiotope located within the 39-59 region of the TCR-V beta 8.2 chain. J Immunol 1992; 149:2803-2809.
141. + T cells in recovery from antigen-induced autoimmune disease. J Exp Med 1993; 178:909-916.
142. Kumar V, Aziz F, Sercarz E, Miller A. Regulatory T cells specific for the same framework 3 region of the Vbeta8.2 chain are involved in the control of collagen II-induced arthritis and experimental autoimmune encephalomyelitis. J Exp Med 1997; 185:1725-1733.
143. + T cells by different mechanisms. J Neuroimmunol 1997; 80:47-64.
144. +, and represented diverse clonal
145. Zipp F, Kerschensteiner M, Dornmair K, Malotka J, Schmidt S, Bender A, et al. Diversity of the anti-T cell receptor immune response and its implications for T cell vaccination therapy of multiple sclerosis. Brain 1998; 121:1395-1407.